Forge Medical has announced the publication of results of an investigator-initiated randomised trial comparing its VasoStat haemostasis device to the TR Band (Terumo Medical) among patients undergoing radial artery coronary and peripheral procedures with planned same-day discharge.
Published in the Journal of Invasive Cardiology, the study authored by Robert L Minor Jr (Billings Clinic, Missoula, USA), the study involved 40 patients without prior radial access undergoing elective coronary, endovascular diagnostic or interventional procedures, who were randomised to receive either VasoStat or TR Band.
The study’s primary outcome was time to haemostasis enabling radial artery compression device (RCD) removal. Minor Jr and colleagues reported significantly shorter times to haemostasis, higher patient satisfaction and fewer device manipulations needed by nursing personnel among the VasoStat group.
All patients were able to be discharged the same day as their procedure, the study reports, adding that Doppler perfusion imaging follow-up within 60 days in all study patients confirmed radial artery patency with no events of radial artery occlusion (RAO) or pseudoaneurysm.
Commenting on the study’s results, Ty Schlander, CEO of Forge Medical, said: “Same-day discharge among elective PCI [percutaneous coronary intervention] and peripheral vascular patients is being used more often by clinicians, hospitals and health systems around the country, with ever higher adoption since the pandemic. We are proud to provide an innovative haemostasis device for radial artery applications differentiated from balloon/band-type devices that enables faster hemostasis and higher patient satisfaction, in alignment with national trends using same-day discharge.”
